Centers | ||
|
|
|
Edinburgh Drug Discovery | EU-OPENSCREEN | Chulalongkorn University Drug Discovery and Drug Development Research Center (Chula4DR) |
Based within the world-leading University of Edinburgh Medical School, Edinburgh Drug Discovery has a track record in successfully translating drug discovery projects from target identification through to clinical evaluation. Key areas of... |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
Chulalongkorn
Drug Discovery and Drug Development Research Center (Chula4DR) was
established in 2017, with the aim to facilitate advancement of academic
drug discovery and drug development research by leveraging innovations
and sciences... Read more |
Partnerships |
Events |
Jobs |
Evotec and Yale University form Open Innovation AllianceEvotec and Yale intend to leverage first rate science performed at Yale University together with Evotec's drug discovery infrastructure and expertise into highly innovative discovery approaches in diseases of high unmet medical need. Initially,... View all Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all Astra Zeneca and Broad Institute to Co-develop Antiviral and Antibacterial DrugsBroad Institute and Astrza Zeneca have entered into a two year collaboration agreement to co-develop antiviral and antibacterial drugs. Screening and target hit to lead chemistry will take place at Broad while Astra Zeneca will be responsible for... View all |
No EVENTS for listing |
No Job Posts |
